# Leuprorelin Acetate DPS (Leuplin DPS) Treatment Quarterly in Patients With Central Precocious Puberty

> **NCT03316482** · PHASE4 · COMPLETED · sponsor: **Jin Soon Hwang** · enrollment: 58 (actual)

## Conditions studied

- Central Precocious Puberty

## Interventions

- **DRUG:** Leuplin DPS 11.25mg

## Key facts

- **NCT ID:** NCT03316482
- **Lead sponsor:** Jin Soon Hwang
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-11
- **Primary completion:** 2019-08-29
- **Final completion:** 2019-12-30
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2020-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03316482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03316482, "Leuprorelin Acetate DPS (Leuplin DPS) Treatment Quarterly in Patients With Central Precocious Puberty". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03316482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*